LIVN vs HAE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
LIVN · LivaNova$89.99 ▼ 1.26%
HAE · Haemonetics$119.93 ▼ 3.37%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- LIVN +76.9%
- HAE +70.2%
Head to head
| Metric | LIVN | HAE |
|---|---|---|
| Price | $89.99 | $119.93 |
| Change today | ▼ 1.26% | ▼ 3.37% |
| Market cap | $4.96B | $5.46B |
| Return, 3 months | +17.7% | +38.5% |
| Return, year to date | +46.3% | +49.6% |
| Return, 1 year | +78.4% | +75.4% |
| P/E (TTM) | 25.8 | 53.1 |
| P/B | 3.6 | 6.1 |
| P/E percentile vs own 5y | 73rd | 81st |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +10.8% | +5.6% |
| Net profit growth (YoY) | +299.7% | -3.0% |
| Gross margin | 68.1% | 59.0% |
| Operating margin | 12.7% | 18.1% |
| Net margin | 12.8% | 7.1% |
| Return on equity | 15.4% | 11.2% |
| Analyst target vs. price | +6.7% | +9.2% |
| Analyst buy share | 100% | 88% |
| RSI (14) | 67 | 55 |
| 30-day volatility | 54.1% | 54.0% |
| Max drawdown, 1 year | -18.9% | -40.1% |
| Trend read | Strong uptrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- HAE is the largest of the group by market value.
- LIVN has returned the most over the past year.
- LIVN carries the lowest trailing P/E.
- LIVN is growing revenue fastest.
- LIVN keeps the most profit per dollar of sales.
- HAE has been the calmest stock over the last 30 days.